Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 125 versus PENBRITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 125 versus PENBRITIN.
AUGMENTIN '125' vs PENBRITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and preventing peptidoglycan cross-linking, leading to cell lysis.
One AUGMENTIN '125' tablet (amoxicillin 125 mg, clavulanate 31.25 mg) orally every 8 hours for mild to moderate infections.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours (prolonged in renal impairment; up to 7-20 hours in anuria). Clavulanate: 0.9-1.2 hours (increased in renal impairment).
0.5-1 hour in normal renal function; extended to 2-6 hours in renal impairment. Hemodialysis shortens half-life.
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~30-50% excreted unchanged in urine. Small amounts eliminated in bile and feces.
Renal: ~75-90% unchanged via glomerular filtration and tubular secretion. Biliary: ~10% in feces. Minor hepatic metabolism to penicilloic acid.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic